Small molecule branched-chain ketoacid dehydrogenase kinase (BDK) inhibitors with opposing effects on BDK protein levels.

However, by day 17, while AUC of BCKAs for the two higher doses were still significantly reduced, the 24 h time points at the lowest doses demonstrated a significant or nearly significant BCKA rebound above vehicle (Supplementary Fig. 6G, K, O ), which occurred in the absence of any changes in plasma drug concentration over the study duration (Supplementary Fig. 6P ) and suggested that PF-07247685 and PF-07238025 elicit similar pharmacological responses.

also in 3,287 other papers